Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study.

MLA

Donadieu, Jean, et al. “Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study.” Journal of Clinical Oncology, vol. 37, no. 31, Nov. 2019, pp. 2857–65. EBSCOhost, https://doi.org/10.1200/JCO.19.00456.

APA

Donadieu, J., Larabi, I. A., Tardieu, M., Visser, J., Hutter, C., Sieni, E., Kabbara, N., Barkaoui, M., Miron, J., Chalard, F., Milne, P., Haroche, J., Cohen, F., Hélias-Rodzewicz, Z., Simon, N., Jehanne, M., Kolenova, A., Pagnier, A., Aladjidi, N., & Schneider, P. (2019). Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. Journal of Clinical Oncology, 37(31), 2857–2865. https://doi.org/10.1200/JCO.19.00456

Chicago

Donadieu, Jean, Islam Amine Larabi, Mathilde Tardieu, Johannes Visser, Caroline Hutter, Elena Sieni, Nabil Kabbara, et al. 2019. “Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study.” Journal of Clinical Oncology 37 (31): 2857–65. doi:10.1200/JCO.19.00456.